Current Report Filing (8-k)
October 23 2020 - 9:21AM
Edgar (US Regulatory)
0000846475
false
0000846475
2020-10-22
2020-10-22
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): October 22, 2020
Zynex, Inc.
(Exact Name of Registrant as Specified in
its Charter)
|
Nevada
|
001-38804
|
90-0275169
|
(State or other jurisdiction
of incorporation)
|
Commission File
Number
|
(I.R.S. Employer Identification
number)
|
9555 Maroon Circle, Englewood, CO 80112
(Address of principal
executive offices) (Zip Code)
Registrant's telephone number, including area code: (303) 703-4906
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
|
Title of each class
|
Ticker symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock, $0.001 par value per share
|
ZYXI
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On October 22, 2020, the board of directors (the “Board”)
of Zynex, Inc. (the “Company’) appointed Neil Friery as the Company’s Chief Operating Officer –
Zynex Monitoring Solutions, Inc., effective November 9, 2020 (the “Effective Date”).
In connection with the appointment, the Company entered into
an employment agreement with Mr. Friery, (the “Friery Employment Agreement”), pursuant to which Mr. Friery shall
receive an annual base salary of $325,000 and shall be eligible to receive incentive compensation in an amount up to $162,500 per
year (the “Incentive Compensation”). Pursuant to the Friery Employment Agreement, in the event that Zynex Monitoring
terminates the Friery Employment Agreement without cause, or Mr. Friery resigns with good reason, Mr. Friery shall receive his
then annual base salary plus 12 months’ worth of his then Incentive Compensation, payable in twelve equal monthly installments.
Additionally, Pursuant to the Friery Employment Agreement, in the event that the Friery Employment Agreement is terminated for
any reason before the end of any quarterly or annual performance period on which the Incentive Compensation is based, Mr. Friery
shall receive a pro-rata portion of the Incentive Compensation that was earned for the quarter/year in which the Friery Employment
Agreement was terminated.
On the Effective Date, Mr. Friery shall receive a signing bonus
of 10,000 restricted shares of Company common stock and $50,000 cash. The 10,000 restricted shares shall vest annually over a four-year
period in increments of 2,500. Additionally, Mr. Friery shall receive quarterly grants of 5,000 restricted shares that shall vest
annually over a four-year period in increments of 1,250.
From July 2010 through January 2020, Mr.
Friery was employed by Zimmer Biomet, a publicly traded medical device manufacturer, where he served as Director of Finance for
the Surgical Division from July 2010 to April 2015 and as Senior Vice President & General Manager of the Surgical Division
from April 2015 to January 2020.
There is no arrangement or understanding
between Mr. Friery and any other person pursuant to which he was selected as an officer of the Company. There is no family relationship
between Mr. Friery and any director or executive officer of the Company and Mr. Friery is not a party to a related party transaction
within the meaning of Item 404(a) of Regulation S-K.
The full text of the Friery Employment Agreement is attached
as Exhibit 10.1 to this Current Report on Form 8-K and is qualified in its entirety thereby.
On October 23, 2020, the Company issued a press release announcing
the appointment of Mr. Friery (the “Press Release”). A copy of the Press Release is furnished hereto as Exhibit
99.1 and is incorporated by reference herein.
|
Item 9.01
|
Financial Statements and Exhibits
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
ZYNEX, INC.
|
|
|
|
|
Dated: October 23, 2020
|
/s/ Daniel Moorhead
|
|
|
Daniel Moorhead
|
|
|
Chief Financial Officer
|
Zynex (NASDAQ:ZYXI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zynex (NASDAQ:ZYXI)
Historical Stock Chart
From Apr 2023 to Apr 2024
